RxDoctor Payments DataLook up a doctor →

Hetal Shah, MD

Family Medicine · Marlton, NJNPI 1497784094

Payments from drug & device makers

$18,376in general payments, 2019–2025

Across 1,241 payments — averaging $14.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Amgen$1K
  • GSK$983
  • Pfizer$969
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$18,04298%
  • Education$3342%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)175$2,173
Novo Nordisk133$1,898
AstraZeneca86$1,564
Amgen(2 entities)84$1,167
GSK78$983
Pfizer85$969
Boehringer Ingelheim53$744
Otsuka America Pharmaceutical, Inc.35$660
Abbott20$598
Lilly USA, LLC38$579
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC43$543
Amarin Pharma, Inc.39$432
Biohaven Pharmaceutical Holding Company Ltd.18$424
Antares Pharma, Inc.14$406
Merck24$344
Lundbeck LLC20$318
Teva Pharmaceuticals USA, Inc.20$297
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)12$259
Eisai Inc.18$256
Kowa Pharmaceuticals America, Inc.16$213
Bayer12$212
Takeda Pharmaceuticals U.S.A., Inc.12$184
Phathom Pharmaceuticals, Inc.11$176
Dexcom, Inc.10$175
Idorsia Pharmaceuticals US Inc10$154
Alkermes, Inc.10$150
Exact Sciences8$141
Astellas Pharma US Inc9$131
Collegium Pharmaceutical, Inc.7$118
Ardelyx, Inc.6$115
IBSA Pharma Inc.7$113
Novartis8$111
Vanda Pharmaceuticals Inc.6$109
Currax Pharmaceuticals LLC8$105
Johnson & Johnson7$102
Almatica Pharma LLC6$89
Axsome Therapeutics, Inc.5$86
Daiichi Sankyo Inc.6$84
Biohaven Pharmaceuticals, Inc.6$82
Adlon Therapeutics L.p.6$79
Halozyme Inc5$79
Corium, LLC6$77
Jazz Pharmaceuticals Inc.5$65
Sanofi-aventis U.S. LLC4$62
Sanofi Pasteur Inc.4$52
E.r. Squibb & Sons, L.L.C.4$48
Bausch Health US, LLC3$46
Ironwood Pharmaceuticals, Inc3$46
Vivus LLC3$38
Harmony Biosciences LLC2$33
Nevro Corp.2$32
Corcept Therapeutics2$31
Neos Therapeutics, LP2$30
Clarus Therapeutics Inc.2$29
Althera Pharmaceuticals LLC2$29
Baxter Healthcare1$29
Kaleo, Inc.2$28
Scilex Pharmaceuticals Inc.2$26
Neotract Inc.1$26
Hikma Pharmaceuticals USA2$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,376 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$139,792
Medicare patients
310
Services billed
3,470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$95,642
MounjaroTirzepatide43$79,216
EliquisApixaban42$60,717
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$49,029
RybelsusSemaglutide29$47,981
JardianceEmpagliflozin29$34,762
Repatha SureclickEvolocumab31$26,119
XareltoRivaroxaban35$24,766
LinzessLinaclotide23$21,310
JanuviaSitagliptin Phosphate12$21,091
JanumetSitagliptin Phos/Metformin Hcl20$16,965
Tresiba Flextouch U-200Insulin Degludec12$16,296
GlyxambiEmpagliflozin/Linagliptin13$14,875
Nucynta ErTapentadol Hcl12$14,343
MyrbetriqMirabegron13$13,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,898$143,623105 claims
Lilly USA, LLCMounjaro$579$79,21643 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Pradaxa$744$61,17571 claims
PfizerEliquis$969$60,71742 claims
GSKTrelegy Ellipta$983$49,02945 claims
MerckJanuvia, Janumet$344$38,05632 claims
Johnson & JohnsonXarelto$102$24,76635 claims
AbbVieLinzess$2,173$21,31023 claims
Collegium Pharmaceutical, Inc.Nucynta Er$118$14,34312 claims
Astellas Pharma US IncMyrbetriq$131$13,20113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Marlton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →